Loading
What changed between revision 1 and revision 3, compared over the article's markdown source with its frontmatter — so a change to status, evidence or reversibility shows up as the edit it is.
Older · revision 1
Import· initial corpus import, not an edit
Initial import of content/glp-1-receptor-agonists.md — the filesystem corpus, unchanged. Not an edit.
18.1 kB
Revision 1
Revision 3
lines 8–16 → 8–167 unchanged lines not shown
categories: ["longevity", "society"]categories: ["longevity", "society"]tags: ["obesity", "incretins", "diabetes", "clinical trials", "metabolic health", "drug access"]tags: ["obesity", "incretins", "diabetes", "clinical trials", "metabolic health", "drug access"]summary: "Drugs that mimic the gut hormone GLP-1 to lower blood glucose and food intake, producing large weight loss that persists only while treatment continues."summary: "Drugs that mimic the gut hormone GLP-1 to lower blood glucose and food intake, producing large weight loss that persists only while treatment continues."updated: "2026-07-27"updated: "2026-11-01"humanEvidence: "Randomized trials in tens of thousands of adults show sustained weight loss and fewer cardiovascular events in people with overweight or obesity and established heart disease; no human trial has tested lifespan."humanEvidence: "Randomized trials in tens of thousands of adults show sustained weight loss and fewer cardiovascular events in people with overweight or obesity and established heart disease; no human trial has tested lifespan."access: "Approved and widely prescribed in most high-income countries for diabetes and weight management; US list prices remain on the order of a thousand dollars a month and payer coverage is heavily restricted."access: "Approved and widely prescribed in most high-income countries; payer coverage is heavily restricted, US list prices are on the order of $1,000 a month beside cheaper self-pay and a $50 Medicare pilot copay, and India has had generic semaglutide since 2026."reversibility: "reversible"reversibility: "reversible"issues: ["Lean-mass loss is described qualitatively; a sourced body-composition figure would be better.", "Pricing and coverage detail is US-centric and moves quickly."]issues: ["Lean-mass loss is described qualitatively; a sourced body-composition figure would be better.", "Pricing and coverage detail is US-centric and moves quickly."]------lines 23–28 → 23–296 unchanged lines not shown
{ "label": "Molecular target", "value": "GLP-1 receptor" }, { "label": "Molecular target", "value": "GLP-1 receptor" }, { "label": "First approval", "value": "2005 (exenatide)" }, { "label": "First approval", "value": "2005 (exenatide)" }, { "label": "Main agents", "value": "Semaglutide, liraglutide, dulaglutide" }, { "label": "Main agents", "value": "Semaglutide, liraglutide, dulaglutide" }, { "label": "Oral agents", "value": "Oral semaglutide, orforglipron" }, { "label": "Related", "value": "Tirzepatide (GIP/GLP-1 dual)" }, { "label": "Related", "value": "Tirzepatide (GIP/GLP-1 dual)" }, { "label": "Approved for aging", "value": "No" }, { "label": "Approved for aging", "value": "No" }, { "label": "Readiness", "value": "TRL 9" } { "label": "Readiness", "value": "TRL 9" }lines 42–79 → 43–8213 unchanged lines not shown
[[ { "value": "2005", "label": "First GLP-1 agonist approved", "note": "exenatide, derived from Gila monster venom peptide" }, { "value": "2005", "label": "First GLP-1 agonist approved", "note": "exenatide, derived from Gila monster venom peptide" }, { "value": "~15%", "label": "Mean weight loss at 68 weeks", "note": "semaglutide in the STEP 1 trial; roughly 2% on placebo" }, { "value": "~15%", "label": "Mean weight loss at 68 weeks", "note": "semaglutide in the STEP 1 trial; roughly 2% on placebo" }, { "value": "0", "label": "Trials with a lifespan endpoint", "note": "as of mid-2026; mortality appears only as a secondary outcome in disease trials" } { "value": "0", "label": "Trials with a lifespan endpoint", "note": "as of November 2026; mortality appears only as a secondary outcome in disease trials" }]]`````` ## How they work## How they work GLP-1 is secreted by enteroendocrine cells lining the distal small intestine and colon when nutrientsGLP-1 is secreted by enteroendocrine cells lining the distal small intestine and colon whenarrive. It amplifies insulin release in a glucose-dependent way, which is why these drugs rarelynutrients arrive. It amplifies insulin release in a glucose-dependent way, which is why these drugscause hypoglycaemia on their own; it suppresses glucagon; it slows gastric emptying; and it bindsrarely cause hypoglycaemia on their own; it suppresses glucagon; it slows gastric emptying; and itreceptors in the hypothalamus and the area postrema, where the signal registers asbinds receptors in the hypothalamus and the area postrema, where the signal registers assatiety.[^drucker2018] The native peptide is destroyed within a few minutes by the enzyme DPP-4, sosatiety.[^drucker2018] The native peptide is destroyed within a few minutes by the enzyme DPP-4, sothe therapeutic problem was never finding the hormone but making it last.the problem for drug developers was how to make the hormone last. Two solutions dominate. The first came from a lizard: exendin-4, isolated from Gila monster venom, isTwo solutions have prevailed. The first came from a lizard: exendin-4, isolated from Gila monsternaturally resistant to DPP-4 and activates the human receptor, and became exenatide.[^eng1992] Thevenom, is naturally resistant to DPP-4 and activates the human receptor, and becamesecond is chemical modification of the human sequence, combining amino-acid substitutions with aexenatide.[^eng1992] The second is chemical modification of the human sequence, combining amino-acidfatty-acid chain that binds circulating albumin and slows both enzymatic degradation and renalsubstitutions with a fatty-acid chain that binds circulating albumin and slows both enzymaticclearance. That combination makes liraglutide a once-daily injection and semaglutide a once-weeklydegradation and renal clearance. That combination makes liraglutide a once-daily injection andone.semaglutide a once-weekly one. Most of the weight loss follows from eating less. That resemblance to a caloric deficit is what firstMost of the weight loss follows from eating less. That resemblance to a caloric deficit is what firstdrew attention from biogerontology, though the analogy to [[caloric-restriction]] is loose: dietarydrew attention from biogerontology, though the analogy to [[caloric-restriction]] is loose: dietaryrestriction experiments hold lean animals below their normal intake, while these drugs mainly removerestriction experiments hold lean animals below their normal intake, while these drugs mainly removeexcess adiposity from people who have it. Whether any of the cardiovascular or renal benefit isexcess adiposity from people who have it. Whether any of the cardiovascular or renal benefit isindependent of weight loss is actively researched and unsettled.independent of weight loss is unsettled and under active research. > [!note] Terminology> [!note] Terminology> GLP-1 and GIP are the two incretin hormones. Semaglutide, made by Novo Nordisk and sold as Ozempic> GLP-1 and GIP are the two incretin hormones. Semaglutide, made by Novo Nordisk and sold as Ozempic> for type 2 diabetes and Wegovy for weight management, acts at the GLP-1 receptor only, as do> for type 2 diabetes and Wegovy for weight management, acts at the GLP-1 receptor only, as do> liraglutide, dulaglutide, and exenatide. Tirzepatide, Eli Lilly's Mounjaro and Zepbound, is a> liraglutide, dulaglutide, and exenatide. Tirzepatide, Eli Lilly's Mounjaro and Zepbound, is a> **dual** GIP and GLP-1 receptor agonist and is not a GLP-1 agonist in the strict sense;> **dual** GIP and GLP-1 receptor agonist and is not a GLP-1 agonist in the strict sense;> retatrutide adds a glucagon receptor arm. Press coverage collapses all of these into "GLP-1s",> [[retatrutide]] adds a glucagon receptor arm. Orforglipron, Lilly's Foundayo, is a GLP-1> agonist that is not a peptide at all but a small molecule taken as a daily pill, while> eloralintide acts at the amylin receptor. Press coverage collapses all of these into "GLP-1s",> which obscures real pharmacological differences.> which obscures real pharmacological differences. ## Development history## Development historylines 84–95 → 87–994 unchanged lines not shown
{ "year": "1992", "title": "Exendin-4 isolated", "text": "John Eng and colleagues characterize a DPP-4-resistant GLP-1 receptor agonist in the venom of the Gila monster, the peptide that becomes exenatide." }, { "year": "1992", "title": "Exendin-4 isolated", "text": "John Eng and colleagues characterize a DPP-4-resistant GLP-1 receptor agonist in the venom of the Gila monster, the peptide that becomes exenatide." }, { "year": "2005", "title": "First approval", "text": "Exenatide is approved in the United States for type 2 diabetes, twice-daily by injection." }, { "year": "2005", "title": "First approval", "text": "Exenatide is approved in the United States for type 2 diabetes, twice-daily by injection." }, { "year": "2010", "title": "Liraglutide reaches market", "text": "Novo Nordisk's daily analogue is approved for type 2 diabetes; a higher-dose version is approved for weight management in 2014." }, { "year": "2010", "title": "Liraglutide reaches market", "text": "Novo Nordisk's daily analogue is approved for type 2 diabetes; a higher-dose version is approved for weight management in 2014." }, { "year": "2016", "title": "Cardiovascular benefit in diabetes", "text": "The LEADER trial reports fewer major cardiovascular events with liraglutide in people with type 2 diabetes at high cardiovascular risk." }, { "year": "2016-2017", "title": "Cardiovascular benefit and semaglutide", "text": "The LEADER trial reports fewer major cardiovascular events with liraglutide in people with type 2 diabetes at high cardiovascular risk (2016). Once-weekly semaglutide is approved for type 2 diabetes in 2017; an oral tablet formulation follows in 2019." }, { "year": "2017", "title": "Semaglutide approved", "text": "The once-weekly analogue is approved for type 2 diabetes; an oral tablet formulation follows in 2019." }, { "year": "2021", "title": "Obesity result and shortage", "text": "STEP 1 reports roughly 15 percent mean weight loss over 68 weeks and semaglutide is approved for weight management; demand outstrips manufacturing capacity for the next several years." }, { "year": "2021", "title": "Obesity result and shortage", "text": "STEP 1 reports roughly 15 percent mean weight loss over 68 weeks and semaglutide is approved for weight management; demand outstrips manufacturing capacity for the next several years." }, { "year": "2022", "title": "Dual agonism", "text": "Tirzepatide, targeting both the GIP and GLP-1 receptors, is approved for type 2 diabetes; SURMOUNT-1 reports mean weight loss around a fifth of body weight at the highest dose." }, { "year": "2022", "title": "Dual agonism", "text": "Tirzepatide, targeting both the GIP and GLP-1 receptors, is approved for type 2 diabetes; SURMOUNT-1 reports mean weight loss around a fifth of body weight at the highest dose." }, { "year": "2023", "title": "Outcomes without diabetes", "text": "SELECT reports fewer major adverse cardiovascular events with semaglutide in adults with overweight or obesity and established cardiovascular disease but no diabetes; tirzepatide is approved for obesity." }, { "year": "2023", "title": "Outcomes without diabetes", "text": "SELECT reports fewer major adverse cardiovascular events with semaglutide in adults with overweight or obesity and established cardiovascular disease but no diabetes; tirzepatide is approved for obesity." }, { "year": "2024", "title": "Beyond weight and glucose", "text": "The FLOW trial, halted early for efficacy the previous year, reports slower kidney-disease progression with semaglutide in type 2 diabetes. Labels expand toward cardiovascular risk reduction and, for tirzepatide, obstructive sleep apnoea." } { "year": "2024", "title": "Beyond weight and glucose", "text": "The FLOW trial, halted early for efficacy the previous year, reports slower kidney-disease progression with semaglutide in type 2 diabetes. Labels expand toward cardiovascular risk reduction and, for tirzepatide, obstructive sleep apnoea." }, { "year": "2025", "title": "Liver, brain and a pill", "text": "Semaglutide receives US accelerated approval for MASH with liver fibrosis, fails to slow early Alzheimer's disease in two phase 3 trials, and in December is approved as the Wegovy pill, the first oral GLP-1 drug for weight management." }, { "year": "2026", "title": "Small molecules and generics", "text": "The FDA approves orforglipron (Foundayo), a non-peptide oral agonist, for weight management, and tirzepatide for cardiovascular risk reduction in type 2 diabetes. Generic semaglutide goes on sale in India and is authorized in Canada." }]]`````` lines 97–106 → 101–1101 unchanged line not shown
The weight results exceed those of any previously approved weight-loss drug. In STEP 1, adults withThe weight results exceed those of any previously approved weight-loss drug. In STEP 1, adults withoverweight or obesity and without diabetes lost roughly 15 percent of body weight on average over 68overweight or obesity and without diabetes lost roughly 15 percent of body weight on average over 68weeks on semaglutide, against about 2 percent on placebo.[^wilding2021] Tirzepatide, at its highest dose inweeks on semaglutide, against about 2 percent on placebo.[^wilding2021] Tirzepatide, at its highestSURMOUNT-1, averaged around a fifth.[^jastreboff2022] Means conceal a wide spread: a substantialdose in SURMOUNT-1, averaged around a fifth.[^jastreboff2022] Means conceal a wide spread: aminority lose very little, and both trials gave every participant diet and activity counsellingsubstantial minority lose very little, and both trials gave every participant diet and activityalongside the injection.counselling alongside the injection. The strongest hard-outcome evidence is the SELECT cardiovascular outcomes trial, which enrolledThe strongest hard-outcome evidence is the SELECT cardiovascular outcomes trial, which enrolledadults with overweight or obesity and established cardiovascular disease but without diabetes, andadults with overweight or obesity and established cardiovascular disease but without diabetes, andlines 111–124 → 115–1404 unchanged lines not shown
difference the trial's statistical hierarchy did not establish as a confirmed result. Regulatorsdifference the trial's statistical hierarchy did not establish as a confirmed result. Regulatorssubsequently expanded semaglutide's label to cardiovascular risk reduction.subsequently expanded semaglutide's label to cardiovascular risk reduction. Tirzepatide's outcomes trial set a different test. SURPASS-CVOT randomized 13,299 adults with type 2diabetes and atherosclerotic cardiovascular disease to tirzepatide or dulaglutide, a GLP-1 agonistalready shown to reduce cardiovascular events, rather than to placebo. Tirzepatide was non-inferior(hazard ratio 0.92, 95.3 percent confidence interval 0.83-1.01), but superiority was notestablished.[^nicholls2025] On that basis the FDA approved Mounjaro in August 2026 to lower the riskof major adverse cardiovascular events in adults with type 2 diabetes at high risk for them; theindication does not extend to obesity without diabetes.[^lillycv2026] Other organ systems have followed. Semaglutide slowed progression of kidney disease in people withOther organ systems have followed. Semaglutide slowed progression of kidney disease in people withtype 2 diabetes and chronic kidney disease.[^perkovic2024] Trials have reported improved symptoms intype 2 diabetes and chronic kidney disease,[^perkovic2024] and in 2025 it received US acceleratedheart failure with preserved ejection fraction, reduced severity ofapproval for metabolic dysfunction-associated steatohepatitis with moderate to advanced liverfibrosis, on the strength of liver-biopsy results at 72 weeks.[^novomash2025] Trials have reportedimproved symptoms in heart failure with preserved ejection fraction, reduced severity of[[sleep-and-longevity|obstructive sleep apnoea]] with tirzepatide, and reduced knee osteoarthritis[[sleep-and-longevity|obstructive sleep apnoea]] with tirzepatide, and reduced knee osteoarthritispain. The failures matter as much: Novo Nordisk reportedpain. The failures are as informative: Novo Nordisk reportedin late 2025 that two large trials of oral semaglutide in early Alzheimer's disease did not slowin late 2025 that two large trials of oral semaglutide in early Alzheimer's disease did not slowprogression of the disease, the most direct test so far of the claim that incretin drugs act broadlyprogression of the disease, the most direct test so far of the claim that incretin drugs act broadlyon age-related disease rather than through metabolism.[^novo2025]on age-related disease rather than through metabolism.[^novo2025] The full results, published in2026, showed no significant difference from placebo on the primary dementia-rating endpoint at 104weeks across 3,808 participants.[^cummings2026] ## The geroscience argument## The geroscience argument lines 133–139 → 149–1558 unchanged lines not shown
age-related conditions is the shape of result the [[geroscience-hypothesis]] predicts, and the shapeage-related conditions is the shape of result the [[geroscience-hypothesis]] predicts, and the shape[[metformin|the TAME trial]] was designed to produce.[[metformin|the TAME trial]] was designed to produce. The case against is that this is disease treatment doing what disease treatment does. RestoringThe case against is that the drugs are doing what any effective disease treatment does. Restoringsomeone with obesity toward the metabolic state of someone who never had it returns them to asomeone with obesity toward the metabolic state of someone who never had it returns them to abaseline; it does not push past it. Nothing in the record shows a change in the underlying rate ofbaseline; it does not push past it. Nothing in the record shows a change in the underlying rate ofaging, and the animal work, overwhelmingly in rodents, has measured metabolic and body-weightaging, and the animal work, overwhelmingly in rodents, has measured metabolic and body-weightlines 165–171 → 181–18725 unchanged lines not shown
produces by any route, but it is a sharper concern here because the drugs are increasingly used byproduces by any route, but it is a sharper concern here because the drugs are increasingly used byolder adults in whom muscle loss is itself a driver of frailty. Trials pairing incretin drugs witholder adults in whom muscle loss is itself a driver of frailty. Trials pairing incretin drugs withantibodies against the activin and [[myostatin-inhibition|myostatin]] pathways are underway, andantibodies against the activin and [[myostatin-inhibition|myostatin]] pathways are underway, andresistance training is the countermeasure with the longest evidence base — one more place whereresistance training is the countermeasure with the longest evidence base. Here, as elsewhere,[[exercise-and-aging|the exercise literature]] is the comparator any drug has to beat.[[exercise-and-aging|the exercise literature]] is the comparator any drug has to beat. ## Risks## Riskslines 182–205 → 198–24010 unchanged lines not shown
> Long-term dosing produced thyroid C-cell tumours in rats and mice, which is the basis for a boxed> Long-term dosing produced thyroid C-cell tumours in rats and mice, which is the basis for a boxed> warning and a contraindication in people with a personal or family history of medullary thyroid> warning and a contraindication in people with a personal or family history of medullary thyroid> carcinoma. Rodent C-cells express the GLP-1 receptor far more abundantly than human ones do, and> carcinoma. Rodent C-cells express the GLP-1 receptor far more abundantly than human ones do, and> no corresponding human effect has been demonstrated. The warning stands because the question is> no corresponding human effect has been demonstrated. The warning reflects an open question; the> open, not because the finding has been shown to transfer.> finding has not been shown to transfer to humans. ## Access and cost## Access and cost Supply constrained the market for several years after 2021, and in the United States that shortageSupply constrained the market for several years after 2021, and in the United States that shortagelegally permitted compounding pharmacies to sell copies, an unregulated parallel supply thatlegally permitted compounding pharmacies to sell copies, an unregulated parallel supply thatcontracted once the shortages were declared resolved. Price is the binding constraint now. US listcontracted once the shortages were declared resolved. In February 2026 the FDA announced it wouldprices sit on the order of a thousand dollars a month before rebates, several times what the samerestrict the ingredients used in mass-marketed compounded versions, the day after a telehealthproducts cost in other high-income countries; manufacturers have opened self-pay channels in thecompany began selling a compounded semaglutide pill, which it then withdrew.[^jacobus2026] Price ismid-hundreds; payers have restricted eligibility or withdrawn coverage for weight indications onthe binding constraint now. US list prices sit on the order of a thousand dollars a month before rebates,budget grounds. Patents on the earlier agents have begun to lapse in some markets, the usual route toseveral times what the same products cost in other high-income countries; manufacturers have openeda price collapse.self-pay channels from about $150 to the mid-hundreds a month;[^lillyfoundayo2026] payers have restricted eligibility or withdrawn coverage forweight indications on budget grounds. Federal deals have started to move those numbers. Agreements the White House announced with Lillyand Novo Nordisk in November 2025 set a $245 monthly Medicare price for Ozempic, Wegovy, Mounjaroand Zepbound, with a $50 monthly copay for beneficiaries, and lower cash prices through thegovernment's TrumpRx site.[^whitehouse2025] A Medicare pilot, the GLP-1 Bridge, began coveringWegovy, the Zepbound KwikPen and Foundayo for weight loss on 1 July 2026 at that copay, with priorauthorization and body-mass and comorbidity criteria, and is scheduled to run to the end of2027.[^fortier2026] Novo Nordisk has said it will cut the US list price of its semaglutide products to$675 a month from January 2027.[^novoprice2026] Uptake is rising faster than prices are falling: Lillyreported third-quarter 2026 revenue up 39 percent, with volume up 53 percent and realized prices down15 percent across its products, led by Mounjaro and Zepbound.[^lillyq32026] Patents on the earlier agents have begun to lapse in some markets, the usual route to a pricecollapse, and semaglutide's have now lapsed in some markets outside the United States. In India, where itspatent expired in March 2026, generic injections launched from about 1,290 rupees ($14) a month(Natco's vial price), against roughly 10,480 rupees for the starting dose of Novo Nordisk's Wegovypen,[^sanjay2026] and weeks later Canada became the first G7 country to authorize genericsemaglutide, approved for type 2 diabetes.[^ireland2026] Obesity prevalence is rising fastest in middle-income countries, where these drugs are furthest outObesity prevalence is rising fastest in middle-income countries, where these drugs are furthest outof reach, making this a clean current example of the pattern described underof reach, making this a clear current example of the pattern described under[[access-and-inequality]]: an effective intervention distributed inversely to need. Cosmetic use by[[access-and-inequality]]: an effective intervention distributed inversely to need. Cosmetic use bypeople at or near typical weight raises the treatment–enhancement boundary thatpeople at or near typical weight raises the treatment-enhancement boundary that[[bioethics-of-enhancement|enhancement ethics]] has argued over for decades, with the added feature[[bioethics-of-enhancement|enhancement ethics]] has argued over for decades, with the added featurethat supply diverted to it is supply unavailable to someone with diabetes. The drugs also anchor athat supply diverted to it is supply unavailable to someone with diabetes. The drugs also anchor aconsumer metabolic-monitoring market, [[continuous-glucose-monitoring]] andconsumer metabolic-monitoring market, [[continuous-glucose-monitoring]] andlines 208–217 → 243–2662 unchanged lines not shown
## Outlook## Outlook The pipeline is moving toward oral small molecules that could be manufactured and distributed likeOral agents have started to arrive. The FDA approved the Wegovy pill, a daily 25 mg semaglutideordinary tablets, toward multi-agonists combining GLP-1 with GIP, glucagon, or amylin receptortablet, for weight management in December 2025,[^novopill2025] and in April 2026 approvedactivity, and toward combinations designed to spare muscle. If oral agents at generic prices arrive,orforglipron as Foundayo, a non-peptide small molecule that Lilly markets as a pill taken at anythe access argument changes shape and the question becomes what happens when a large fraction of atime of day without food or water restrictions.[^lillyfoundayo2026] In its 72-week phase 3 trial inadults with obesity, the top dose of orforglipron lowered body weight by 11.2 percent against 2.1percent on placebo,[^wharton2025]a smaller average than the injectable trials above reported, though the trials are not directlycomparable. Lilly reported $184 million of Foundayo sales in the third quarter of 2026, its secondquarter on the market.[^lillyq32026] The pipeline is also moving toward multi-agonists combining GLP-1 with GIP, glucagon, or amylinreceptor activity, and toward combinations designed to spare muscle. In a 48-week phase 2b trial inadults with overweight or obesity and type 2 diabetes, Lilly reported that the amylin agonist eloralintide added tothe top dose of tirzepatide produced 23.3 percent average weight loss on the company's efficacyestimand, against 14.8 percent for tirzepatide alone, with more discontinuations for adverse eventsin the combination arms than with tirzepatide alone. Those are company-reported conference results,not a peer-reviewed paper, and Lilly plans phase 3 trials from the end of 2026.[^lillyelora2026] Iforal agents at generic prices arrive, the access argument changes shape and the question becomes what happens when a large fraction of apopulation takes an appetite-modifying drug indefinitely, a natural experiment with no precedent andpopulation takes an appetite-modifying drug indefinitely, a natural experiment with no precedent andno control group.no control group. lines 221–227 → 270–2763 unchanged lines not shown
establish and correspondingly easy to assert. The stronger and more testable claim is narrower: thatestablish and correspondingly easy to assert. The stronger and more testable claim is narrower: thatthey compress the years of illness at the end of a life without moving its end, which isthey compress the years of illness at the end of a life without moving its end, which is[[compression-of-morbidity]] rather than any change in [[maximum-human-lifespan]]. That is a large[[compression-of-morbidity]] rather than any change in [[maximum-human-lifespan]]. That is a largeachievement, and it is not the one the popular framing has settled on.achievement, but not the one the popular framing has settled on. ## See also## See also lines 244–247 → 293–31116 unchanged lines not shown
[^wilding2022]: `paper` Wilding, J.P.H. et al. "Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension." *Diabetes, Obesity and Metabolism*, 2022.[^wilding2022]: `paper` Wilding, J.P.H. et al. "Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension." *Diabetes, Obesity and Metabolism*, 2022.[^perkovic2024]: `paper` Perkovic, V. et al. "Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes." *New England Journal of Medicine*, 2024.[^perkovic2024]: `paper` Perkovic, V. et al. "Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes." *New England Journal of Medicine*, 2024.[^novo2025]: `statement` Novo Nordisk. Headline results announcement for the evoke and evoke+ trials of oral semaglutide in early Alzheimer's disease, 2025. {A sponsor announcement of a negative result, reported before the full trial publication.}[^novo2025]: `statement` Novo Nordisk. Headline results announcement for the evoke and evoke+ trials of oral semaglutide in early Alzheimer's disease, 2025. {A sponsor announcement of a negative result, reported before the full trial publication.}[^nicholls2025]: `paper` Nicholls, S.J. et al. "Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes." *New England Journal of Medicine* 393:2409-2420, 2025. https://doi.org/10.1056/NEJMoa2505928 {The comparator was dulaglutide, an active drug with proven cardiovascular benefit, so the trial does not measure tirzepatide against placebo.}[^lillycv2026]: `statement` Eli Lilly and Company. "FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes." Press release, 28 August 2026. https://www.prnewswire.com/news-releases/fda-approves-lillys-mounjaro-tirzepatide-to-reduce-cardiovascular-risk-in-adults-with-type-2-diabetes-302862415.html[^novomash2025]: `statement` Novo Nordisk. "Wegovy approved in the US for the treatment of MASH." Company announcement filed on Form 6-K, 15 August 2025. https://www.sec.gov/Archives/edgar/data/353278/000117184325005454/f6k_081525.htm {An accelerated approval resting on biopsy findings from part 1 of the ESSENCE trial, not on liver outcomes such as cirrhosis.}[^cummings2026]: `paper` Cummings, J.L. et al. "Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials." *The Lancet* 407:2167-2179, 2026. https://doi.org/10.1016/S0140-6736(26)00459-9[^jacobus2026]: `news` Jacobus, N. "Hims & Hers Pulls Access to Compounded Semaglutide Pill Following Controversial Launch." *Pharmaceutical Executive*, 9 February 2026. https://www.pharmexec.com/view/hims-hers-pulls-access-compounded-semaglutide-pill-following-controversial-launch[^whitehouse2025]: `statement` The White House. "Fact Sheet: President Donald J. Trump Announces Major Developments in Bringing Most-Favored-Nation Pricing to American Patients." 6 November 2025. https://www.whitehouse.gov/fact-sheets/2025/11/fact-sheet-president-donald-j-trump-announces-major-developments-in-bringing-most-favored-nation-pricing-to-american-patients/[^fortier2026]: `news` Fortiér, J. "Some Medicare beneficiaries can now get popular obesity drugs for $50 a month." KFF Health News, republished by VPM, 6 May 2026, updated 1 July 2026. https://www.vpm.org/2026-05-06/some-medicare-beneficiaries-can-now-get-popular-obesity-drugs-for-50-a-month[^novoprice2026]: `statement` Novo Nordisk. "Novo Nordisk announces significant reduction in US list price for Wegovy, Ozempic, and Rybelsus." Company announcement, 24 February 2026. https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916504 {The cut applies to list price only; the company states it does not change direct-to-patient self-pay prices.}[^lillyq32026]: `statement` Eli Lilly and Company. "Lilly reports third-quarter 2026 financial results." Press release filed as Exhibit 99.1 to Form 8-K, 29 October 2026. https://www.sec.gov/Archives/edgar/data/0000059478/000005947826000104/q326lillysalesandearningsp.htm {Company-wide figures: the volume and price changes cover all Lilly products, though Mounjaro and Zepbound drove most of them.}[^sanjay2026]: `news` Sanjay, S. "Ozempic Copies at $14 in India as Novo Patent Expires." Bloomberg, via Bloomberg Law, 21 March 2026. https://news.bloomberglaw.com/health-law-and-business/ozempic-copies-to-cost-14-in-india-as-generic-glp-1-era-starts[^ireland2026]: `news` Ireland, N. "Health Canada approves 2nd generic version of Ozempic, and it's Canadian." The Canadian Press, via National Newswatch, 1 May 2026. https://nationalnewswatch.com/2026/05/01/health-canada-approves-2nd-generic-version-of-ozempic-and-its-canadian[^novopill2025]: `statement` Novo Nordisk. "Wegovy pill approved in the US as first oral GLP-1 for weight management." Company announcement, 22 December 2025. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916472[^lillyfoundayo2026]: `statement` Eli Lilly and Company. "FDA approves Lilly's Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions." Press release, 1 April 2026. https://www.prnewswire.com/news-releases/fda-approves-lillys-foundayo-orforglipron-the-only-glp-1-pill-for-weight-loss-that-can-be-taken-any-time-of-day-without-food-or-water-restrictions-302731485.html[^wharton2025]: `paper` Wharton, S. et al. "Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment." *New England Journal of Medicine* 393:1796-1806, 2025. https://doi.org/10.1056/NEJMoa2511774 {ATTAIN-1 excluded people with diabetes; the 11.2 percent figure is the treatment-regimen estimand, which counts participants who stopped the drug.}[^lillyelora2026]: `statement` Eli Lilly and Company. "Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes." Press release, 30 September 2026. https://www.prnewswire.com/news-releases/lillys-eloratzp-combination-of-eloralintide-and-tirzepatide-delivered-greater-weight-loss-and-a1c-reduction-vs-tirzepatide-15-mg-in-adults-with-obesity-and-type-2-diabetes-302894480.html {A sponsor release of conference results; the trial's primary comparison was against placebo, not against tirzepatide alone.} removed, struck through added, underlinedLine numbers count the serialised markdown of each revision, frontmatter included.
203 lines are the same in both revisions, and 99 of them are not shown. Neither revision here is necessarily the current article — read GLP-1 receptor agonists for the text this wiki stands behind today.